American Origin Unverified
This profile is unclaimed and has not been independently reviewed.
Claim & get verified
Lyra Therapeutics, Inc.
$0.60
-24.99%
OTC: LYRA · 15-min delayed
$398.0KRevenue · FY2025
-$28.9MNet income
LYRAOTC
About Lyra Therapeutics, Inc.
LYRA THERAPEUTICS INC
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Reported figures
Financial summary
- Revenue FY2025
- $398.0K
- Net income
- -$28.9M
- Total assets
- $36.1M
- Operating margin
- -7794.5%
- Net margin
- -7266.1%
Source: SEC EDGAR · updated Jun 8, 2026
Multi-year
Revenue & profit trend
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue Net income
FY 2025
Financial statements
Income statement
- Revenue
- $398.0K
- Operating expenses
- $31.4M
- Operating income
- -$31.0M
- Income tax
- $11.0K
- Net income
- -$28.9M
- EPS (basic)
- $-18.62
- EPS (diluted)
- $-18.62
Balance sheet
- Total assets
- $36.1M
- Current assets
- $16.3M
- Total liabilities
- $46.8M
- Current liabilities
- $9.5M
- Shareholders’ equity
- -$10.7M
Cash flow
- Operating cash flow
- -$28.9M
- Investing cash flow
- -$98.0K
- Financing cash flow
- $4.3M
- Net cash flow
- -$24.7M
Statements via Polygon.io (SEC filings)
- EPS (diluted)
- $-18.62
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
Market data by Polygon.io · prices are 15-minute delayed
Auto-generated
At a glance
- Reported a net loss of $28.9M in FY2025.
- Revenue grew 40% from FY2021 to FY2025.
- Trading 98% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Lyra Therapeutics, Inc..
Write a review
Newsroom
News about Lyra Therapeutics, Inc.
Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS)
Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025
Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis
Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings
Lyra Therapeutics Announces Cost-Cutting Measures to Preserve Capital
Where Lyra Therapeutics Stands With Analysts
News & sentiment via Polygon.io
Explore
Browse all →
